Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
There is limited long-term data on the effect of interferon-beta1b (IFN-beta1b) on disability progression in patients with multiple sclerosis (MS). There is also no reliable way of predicting individual responses to IFN-beta1b treatment. This prospective study investigated early clinical prognostic markers of disease activity and progression in 115 patients with relapsing-remitting MS (RRMS) treated with IFN-beta1b for almost 5 years. The study also compared progression of disability in IFN-beta1b-treated patients with a historic untreated cohort of MS patients (n = 44). The number of relapses in the first 2 years of MS and in the 2 years before treatment predicted an early relapse after IFN-beta1b treatment. The IFN-beta1b-treated group experienced a slower progression of disability than the untreated cohort, suggesting that IFN-beta1b treatment delays progression of disability in RRMS.
Carmona
Olga
O
Hospital de Figueres, Figueres, Girona, Spain.
Casado
Virginia
V
Moral
Ester
E
Alonso-Magdalena
Lucía
L
Martínez-Yélamos
Antonio
A
Martínez-Yélamos
Sergio
S
Martín-Ozaeta
Gisela
G
Arbizu
Txomin
T
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D055118:Medication Adherence; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta